Research Article
SLC2A9 Gene Polymorphism Is Associated with Elevated Serum Uric Acid Caused by Pyrazinamide
Table 1
Characteristics of patients in low-risk and high-risk groups.
| | Variables | Low-risk group (n = 60) | High-risk group (n = 83) | value |
| | Gender | | Male (%) | 29 (48.30) | 42 (50.60) | 0.789 | | Female (%) | 31 (51.70) | 41 (49.40) | | | Age (years) | 47.22 ± 15.59 | 47.24 ± 16.12 | 0.993 | | BMI (kg/m2) | 26.51 ± 3.71 | 27.17 ± 3.35 | 0.266 | | Hypertension (%) | 24 (40.0) | 27 (32.50) | 0.357 | | Diabetes mellitus (%) | 23 (38.30) | 27 (32.50) | 0.473 | | Smoking history (%) | 10 (16.70) | 17 (20.50) | 0.565 | | Drinking history (%) | 7 (11.70) | 23 (27.70) | | | Place of residence | | Urban (%) | 38 (63.30) | 58 (69.90) | 0.411 | | Rural area (% | 22 (36.70) | 25 (30.10) | | | Initial SUA (mol/L) | 229.42 ± 35.98 | 219.63 ± 35.93 | 0.110 | | SUA after 2-week treatment (mol/L) | 406.78 ± 101.40 | 527.03 ± 113.53 | | | SUA after 6-week treatment (mol/L) | 397.54 ± 83.53 | 558.83 ± 124.57 | |
|
|
The difference was statistically significant. BMI, body mass index; SUA, serum uric acid. |
